Author

Richard G. Yau

ORCID 0000-0002-9252-9221Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell-cell communication· 1 Research Focus:clustering· 1 Research Focus:drug response / drug discovery· 1 Assay:imaging· 1 Organism:mouse· 1 Organism:non-human primate· 1

Frequent Co-Authors

C. B. Collins· 1 shared Chris LangsdorfiD· 1 shared Christopher E. MasoniD· 1 shared Christos M. KougentakisiD· 1 shared Cyra K. Fung· 1 shared Darin J. Hildebrandt· 1 shared Darrin A. Lindhout· 1 shared Diana LiiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCell Biology

C. B. Collins

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

CellCage™ Technology Enables High-throughput Isolation of Defined Cell Combinations to Resolve the Determinants of CAR-T mediated Cytotoxicity

Richard G. Yau, Shreya S. Deshmukh, Makenzie Sacca, Ria Gupta, Yanping Yang, Mehdi Mohseni, Liz Y. Wu, Filiz Gorpe Yasar, Shan Sabri, Teresa Ai, Tarun K. Khurana, Shawn Levy, Pier Federico Gherardini, Christopher E. Mason, Moonsoo M. Jin, Gary P. Schroth

The paper introduces CellCage™ technology to isolate defined cell combinations for high-throughput analysis of CAR-T cell cytotoxicity, revealing functional heterogeneity and cooperative behavior in T cell-mediated killing.

bioRxiv · Aug 25, 2026 · PreprintImmunology

Catalytic degradation of circulating targets with FcRn-mediated cycling LYTACs

Christos M. Kougentakis, Matthew J. Shurtleff, Rachel M. Lieser, Tao Chen, C. B. Collins, Isabel E. Johnson, Siyi Gu, Keith T. Akama, Kyle H. Doran, Cyra K. Fung, Darin J. Hildebrandt, Rozhan Khaleghi, Diana Li, Steve Rank, Thomas-Toan Tran, , Nicholas A. Lind

This paper introduces cataLYTACs, a new therapeutic modality that efficiently and durably degrades circulating proteins like IgE in vitro and in vivo, outperforming traditional inhibitors.

bioRxiv · Jan 12, 2025 · PreprintCell Biology